Are Exosome Skincare Products Cosmetics or Drugs in Canada? Health Canada's April 2026 Classification Notice, Decoded for Brands

What the Final Notice Actually Does

Health Canada's Final Notice does not declare every exosome-containing topical product a drug. Instead, it formalises a case-by-case classification approach based on three core considerations that the Notice explicitly names: product representation, level of action, and composition. Source of material — human, animal, plant, or synthetic — and how the product is intended to be used are integral to that assessment.

The Final Notice clarifies that:

• Topical products containing human-derived exosomes, human extracellular vesicles, or human cell-conditioned media that make structure/function or therapeutic claims will be regulated as drugs under the Food and Drugs Act and the Food and Drug Regulations. A "No Objection Letter" (for clinical trials) or a Notice of Compliance and Drug Identification Number (DIN) is required prior to sale.
• Where the active material is derived from human cells or tissues, products are also subject to the well-recognised risks associated with materials of human origin — transmission of infectious diseases and adventitious agents — and Health Canada specifically flags these in the Notice. Depending on upstream sourcing and the nature of the manufacturing process, the Safety of Human Cells, Tissues and Organs for Transplantation Regulations (the CTO Regulations, SOR/2007-118) may also be engaged at the donor/establishment level.
• Plant-derived, animal-derived, and synthetic "exosome" claims are not exempt from review. The Notice expressly confirms that non-human-source products are subject to the same classification analysis — Health Canada assesses the entire representation of the product, including marketing copy, before-and-after imagery, influencer content, and route of administration, regardless of the stated source.
• Cosmetic Notification Forms (CNFs) are not approvals. The Notice reiterates that submission of a CNF "does not constitute an approval for sale, an agreement that the product is classified as a cosmetic, nor that the product complies with all legislative requirements." A CNF for a product that should have been classified as a drug, biologic, or natural health product (NHP) is not a defence.

For brands, the practical implication is sharp: the Final Notice closes the regulatory grey zone that allowed exosome products to be sold under cosmetic CNFs while making implicit or explicit "regenerative," "stem cell," "growth factor," or "tissue repair" claims. That zone no longer exists.

For the full official text, see Health Canada's Final Notice: Classification of Topical Products Containing Human-Derived Exosomes, Extracellular Vesicles, or Cell-Conditioned Media and the Cosmetics Alliance Canada — Final Notice Summary.

What Exosomes, Extracellular Vesicles, and Cell-Conditioned Media Actually Are

To understand why Health Canada has acted, it helps to understand the underlying biology and why exosomes have become a regulatory pressure point.

• Exosomes are nanoscale (typically 30–150 nm) lipid-bilayer vesicles released by living cells. They carry biologically active cargo — proteins, lipids, microRNAs, messenger RNAs — and act as cell-to-cell signalling agents.
• Extracellular vesicles (EVs) is the broader umbrella term that includes exosomes and other vesicle subtypes (microvesicles, apoptotic bodies) released by cells.
• Cell-conditioned media (CCM) is the liquid in which cultured cells have been grown. It contains the proteins, growth factors, cytokines, and vesicles those cells have secreted.

When derived from human sources — most commonly mesenchymal stem cells, fibroblasts, keratinocytes, or platelet-rich plasma — these materials carry pharmacologically active components. That is precisely the property that has driven their adoption in "regenerative" skin care, post-laser recovery products, micro-needling topicals, and hair-loss serums. It is also the property that pulls them out of the cosmetic definition and into the drug, biologic, or human-cells-and-tissues framework.

The Six Classification Triggers — MFLRC's Practical Framework

Health Canada's Final Notice formally names three core considerations: product representation, level of action, and composition. In practice, applying those three considerations to real exosome / EV / CCM products requires examining six interrelated factors — MFLRC's working framework that incorporates Health Canada's three statutory considerations alongside the practical inputs that determine how Health Canada classifies a real product. No single trigger is determinative — the assessment is holistic — but any one trigger can be enough to push a product across the cosmetic–drug line.

1. Source of the Vesicles

Are the exosomes, EVs, or CCM derived from human cells or tissues, animal sources, plant sources, or are they fully synthetic? Human-derived material almost invariably pulls the product into the biologic/drug framework, particularly where the product makes any structure/function or therapeutic claim. Depending on how the source material is collected and processed upstream, the Safety of Human Cells, Tissues and Organs for Transplantation Regulations (SOR/2007-118) may also be engaged at the donor and establishment level. Animal-derived material is similarly scrutinised. Plant-derived and synthetic vesicles are not automatically drug-classified — but as discussed below, they are not automatically cosmetic either.

2. Processing and Manipulation

How the vesicles are isolated, purified, concentrated, sterilised, or otherwise manipulated is a core consideration. Material that has been subject to more than minimal manipulation, or that has been combined with other biologically active substances, is more likely to be classified as a drug or biologic. Sterile filtration, lyophilisation, encapsulation, and combination with peptides or growth factors all raise the classification risk.

3. Intended Use

The cosmetic definition under section 2 of the Food and Drugs Act limits cosmetics to products intended for cleansing, beautifying, promoting attractiveness, or altering appearance. Anything beyond that — restoring tissue, accelerating healing, stimulating cell function, treating a condition — falls outside the cosmetic definition.

4. Representations and Claims

This is where most brands stumble. Phrases such as "regenerate," "heal," "stimulate cell renewal," "restore growth," "reverse hair loss," "stem cell therapy," "boost collagen synthesis," or "activate skin's repair process" are structure/function or therapeutic claims. Under section 9 of the Food and Drugs Act, making such representations turns the product into a drug — regardless of the company's intent or the label's "cosmetic" designation. Marketing copy, social media, influencer content, package inserts, sales-staff scripts, and clinical-looking before-and-after imagery are all part of the "representation" Health Canada will assess.

5. Route of Administration

Topical application to intact, healthy skin is the cosmetic-aligned route. Health Canada's Final Notice is explicit on this point: cosmetics must "exhibit a lack of percutaneous absorption and should not have to be absorbed systemically to achieve the intended effect," and "indications of use that would facilitate percutaneous absorption (e.g., microneedling) are not consistent with cosmetics." Application during or immediately after a skin-breaching procedure — micro-needling, fractional laser, micro-channelling, radiofrequency micro-needling, scalp dermastamping — is therefore explicitly out of scope for cosmetic classification. Products administered through injection (intramuscular, subcutaneous, intravenous) are not cosmetics under any circumstances. Where the product is intended for use on broken or compromised skin, on mucous membranes, or in conjunction with a device that breaches the skin barrier, the product is almost certainly a drug, and frequently a biologic, regardless of how the label characterises it.

6. Target Population

A product positioned for the general consumer market is assessed differently from a product positioned for patients with skin disease, post-acne scarring, alopecia, post-surgical recovery, or other clinical conditions. Targeting a diseased or symptomatic population is a strong indicator of drug classification.

When an Exosome Topical Becomes a Drug, a Biologic, or a Cells-and-Tissues Product

The Final Notice operationalises three distinct regulatory pathways depending on how the six triggers play out.

Pathway 1 — Drug (DIN-Required)

If the product makes therapeutic or structure/function claims, or is intended for use on broken skin or in patients with disease — but the active material is not derived from human cells, tissues, or organs — the product is regulated as a drug. This requires:

• A Drug Identification Number (DIN) issued by Health Canada
• A New Drug Submission (NDS) or Abbreviated New Drug Submission (ANDS) depending on novelty
• Establishment Licensing (DEL) for the manufacturer and importer
• GMP-compliant manufacturing, full chemistry, manufacturing and controls (CMC) documentation, and where applicable, non-clinical and clinical safety/efficacy data
• Compliant labelling, professional information, and advertising — pre-clearance for therapeutic advertising directed at health care professionals applies

Pathway 2 — Biologic (Schedule D)

Where the product contains material derived from human cells, tissues, or human cell-conditioned media and is intended to have a therapeutic effect, it is regulated as a biologic drug under Schedule D of the Food and Drugs Act. This pathway is significantly more demanding than a small-molecule DIN:

• The submission is reviewed by Health Canada's Biologic and Radiopharmaceutical Drugs Directorate (BRDD)
• Full donor screening, traceability, and bioburden / viral safety documentation is required
• Lot-by-lot release testing and biologic-grade GMP apply
• Post-market pharmacovigilance, periodic safety update reports, and stricter advertising controls follow approval

Pathway 3 — Upstream Cells, Tissues and Organs (CTO Regulations)

Where source material is collected from human donors to produce exosomes, EVs, or cell-conditioned media, upstream collection and establishment activities may engage the Safety of Human Cells, Tissues and Organs for Transplantation Regulations (SOR/2007-118). The CTO Regulations apply to establishments that handle, process, distribute, or import minimally manipulated human cells and tissues for homologous use for transplantation. While a finished topical exosome product is not itself a transplant, the upstream sourcing chain — donor selection, screening, retrieval, processing, and traceability — must still meet the safety expectations Health Canada attaches to materials of human origin, including:

• Donor suitability assessment (screening, testing, medical/social history)
• Retrieval, processing, preservation, storage, and distribution controls
• Establishment registration and oversight by Health Canada
• Traceability from donor through to finished product

Health Canada's Final Notice expressly highlights "the risks present with all materials of human origin, specifically, the transmission of infectious diseases and adventitious agents." Brands sourcing human-derived raw materials must be able to document a sourcing chain that addresses those risks. For the full regulatory text, see the Safety of Human Cells, Tissues and Organs for Transplantation Regulations on the Justice Laws website.

In practice, most commercial human-exosome topical products currently advertised in Canada under a cosmetic CNF will need to be repositioned — either reformulated and de-claimed to remain cosmetics, withdrawn, or moved onto the drug or biologic pathway with appropriate authorisation.

"Plant-Derived" and "Synthetic" Exosome Claims — How Health Canada Views Them

A common reaction to the Final Notice has been to pivot marketing toward "plant-derived exosomes" (typically from sources such as ginger, grape, citrus, or callus cultures) or "synthetic exosome-like nanovesicles." Brands have assumed that because the Final Notice is framed around human-derived materials, plant and synthetic variants fall outside it.

That is a misreading. The Final Notice's title focuses on human-derived material, but Health Canada has been consistent in stating that:

• Claims and intended use govern classification, not source alone. A plant-derived exosome serum that claims to "regenerate skin," "stimulate fibroblasts," or "reverse photo-ageing" is a drug claim regardless of where the vesicles came from.
• Biological activity is biological activity. If a plant-derived or synthetic vesicle is represented as having pharmacological effects on skin cells, the product is positioned as a drug.
• Safety data are still required. Cosmetics must be safe under normal conditions of use. Novel nanoscale ingredients — plant-derived or synthetic — require substantiation of safety, ingredient identity, and quality. "Plant-derived exosome" without characterisation data is not a defensible cosmetic ingredient claim.

The Final Notice should be read alongside Health Canada's longstanding Drug or Cosmetic? — Classification Guidance, which has always treated source as one factor among many. The Final Notice removes any remaining doubt that a "plant-derived" label will not rescue a structure/function claim.

Label, Advertising, and Cosmetic Notification Form (CNF) Changes for In-Market Products

If you have an exosome / EV / CCM product currently in the Canadian market under a CNF, the Final Notice triggers an immediate compliance review. The most common required changes include:

• Label revision. Remove all therapeutic, structure/function, or "regenerative" claims if the product is to remain a cosmetic. This is rarely the commercial preferred path, but it is the cleanest if reformulation/reclassification is not feasible.
• CNF withdrawal or amendment. A CNF filed for a product that should have been classified as a drug, biologic, or NHP must be addressed — either by amending the product, withdrawing the CNF, or pursuing the correct regulatory pathway.
• Advertising and digital content review. Every website page, product page, social media post, paid ad, influencer reference, and clinic/medi-spa marketing asset must be reviewed against section 9 of the Food and Drugs Act (false, misleading, or deceptive representations) and section 3 of the Act read with Schedule A.1 (prohibited disease/condition advertising; Schedule A was renumbered to Schedule A.1 under amendments associated with Vanessa's Law).
• Sales-channel review. Medi-spas, dermatology clinics, and aesthetic professionals are frequent re-sellers of exosome products. Their in-clinic claims, brochures, and post-procedure protocols are part of the manufacturer's representation chain.
• Import and customs review. Border holds under section 30 of the Food and Drugs Act are an enforcement tool Health Canada and the Canada Border Services Agency are actively using for biologic-adjacent imports. Brands importing exosome products without the correct licences face seizure and detention.

The Final Notice is not retroactive in a way that absolves products already on shelves. Continued sale of a non-compliant product is a fresh offence each day it remains in distribution.

Enforcement Risk Under Sections 9 and 30 of the Food and Drugs Act

The two enforcement levers most relevant to exosome products are:

• Section 9 — False, misleading, or deceptive labelling and advertising. A cosmetic that carries drug-level claims is treated as falsely or misleadingly labelled. The remedy is removal, recall, and prosecution.
• Section 30 — Importation prohibitions. Products that do not comply with the Act may not be imported into Canada. Customs detentions, refusal-of-entry decisions, and CBSA notices to the importer are the visible enforcement actions.

Health Canada also has authority under the Food and Drugs Act and the Vanessa's Law amendments to issue public advisories, mandatory recalls, terms and conditions on licences, and administrative monetary penalties. For a small or mid-sized brand, a public advisory naming the product is often more damaging than the regulatory penalty itself.

How Canada's Position Compares Internationally

Canadian regulators are operating within a tightening global consensus that exosome topical products require a more rigorous framework than ordinary cosmetics.

• United States — FDA. Between 2023 and 2025, the U.S. Food and Drug Administration issued multiple untitled letters and warning letters to clinics and manufacturers marketing exosome products with regenerative or therapeutic claims — including letters to Regenerelle (May 2023), Kimera Labs, Evolutionary Biologics (late 2024), Chara Biologics (early 2025), and New Life Medical Services (September 2025). The FDA's stated position is that "as a general matter, exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products" and are subject to premarket review and approval requirements. No exosome product has been approved by the FDA for any therapeutic indication, and clinical use outside an authorised Investigational New Drug (IND) is treated as unlawful.
• European Union. Under Regulation (EC) No 1223/2009 on Cosmetic Products, human-derived exosomes are listed as a prohibited substance in Annex II (entry 1657 in current consolidated text; widely cited as entry 416 in regulatory commentary). Human cells, tissues, and cellular products simply cannot be used as cosmetic ingredients in the EU or UK. Where human-cell-derived materials are intended for therapeutic use, they fall under the Advanced Therapy Medicinal Product (ATMP) regime overseen by the European Medicines Agency.
• South Korea — MFDS (formerly KFDA). Effective 21 January 2025, the Korean Ministry of Food and Drug Safety expanded its prohibited expressions for cosmetic labelling and advertising to explicitly prohibit the term "exosome" in cosmetic marketing. Human-derived cells, tissues, and culture media are likewise prohibited as cosmetic ingredients (subject to narrow exceptions). Human-cell-derived exosome products intended for therapeutic skin use are treated as biopharmaceuticals subject to clinical trial authorisation and biologic licensing.

Canada's Final Notice is therefore not an outlier — it is consistent with how comparable agencies are treating the same product class. A brand operating compliantly in Canada will generally be on safer ground when entering the U.S. and EU markets as well.

A Practical Decision Tree: Am I a Cosmetic, an NHP, a Drug, or a Biologic?

To turn the Final Notice into an operational tool, the following framework — applied product by product — is the most efficient way to reach a defensible classification.

1. Is the active material derived from human cells, tissues, or human cell-conditioned media? If yes, the product is almost certainly a drug + biologic and engages the CTO Regulations. There is no cosmetic, NHP, or "Class II device" route.
2. If the material is animal-, plant-, or synthetic-derived, does the product make any claim that goes beyond cleansing, beautifying, altering appearance, or perfuming? If yes — for example, "regenerate," "heal," "stimulate," "repair," "reverse," "treat" — the product is a drug.
3. Is the product positioned, marketed, or commonly used for a skin or hair condition (acne, eczema, alopecia, post-surgical scarring, photo-damage treatment)? If yes, it is a drug by representation.
4. Is the product intended for use during or after a procedure that compromises the skin barrier (micro-needling, fractional laser, micro-channelling)? If yes, the product is a drug, often a biologic, and the device-cosmetic combined-use considerations also apply.
5. Is the product a "natural" or botanical ingredient making a health-maintenance, modification of organic function, or risk-reduction claim — without crossing into therapeutic territory? If yes, the product may be a Natural Health Product (NHP) requiring an NPN under the Natural Health Products Regulations.
6. Does the product cleanse, beautify, alter appearance, or perfume only, with no biologically active claim, no broken-skin route, and no structure/function language anywhere in the marketing chain? If yes — and only then — the product is a cosmetic requiring a CNF within ten days of first sale.

A documented walk through these six questions, supported by file evidence, is what defensible regulatory classification looks like.

Reformulation and Relabelling Readiness Checklist

For brands holding exosome / EV / CCM products today, the practical workstream looks like this:

1. Inventory every SKU containing exosomes, EVs, conditioned media, "stem cell extract," "growth factor complex," or analogous ingredients — across owned brands, private label, and contract-manufactured lines.
2. Map the source for each SKU: human, animal, plant, or synthetic. Confirm by Certificate of Analysis and supplier documentation.
3. Map the representation chain: product label, package inserts, e-commerce product pages, brand website, social media (all platforms), influencer agreements, retailer pages, distributor materials, medi-spa partner content.
4. Identify every claim — explicit and implied — that could trigger a drug classification under the Food and Drugs Act.
5. Decide pathway per SKU: (a) reformulate and de-claim to remain a cosmetic; (b) pursue NHP licensing if defensible; (c) pursue drug/biologic submission for genuinely therapeutic positioning; (d) discontinue.
6. Withdraw or amend CNFs that no longer reflect the product's regulatory pathway.
7. Revise labels, websites, advertising, and partner content in lockstep — a label change without a website change does not resolve a section 9 violation.
8. Strengthen supplier QA documentation, including identity testing, characterisation, and (where required) donor screening and traceability records.
9. Brief retail, sales, and medi-spa partners on the regulatory boundary — their in-clinic claims attach to your product.
10. Document the decision and the evidence in a regulatory file your team — and a Health Canada inspector — can defend.

How MFLRC Helps Skin-Care, Hair-Care, and Medi-Aesthetic Brands Respond

At MF License & Regulatory Consultants (MFLRC), we work at exactly the regulatory intersection the Final Notice creates: cosmetics, natural health products, pharmaceuticals, and biologics. Our team brings 20+ years of senior-led Canadian regulatory experience across Cosmetics & Personal Care, Pharmaceuticals, Natural Health Products, and Regulatory Affairs, and we have been advising brands on the exosome classification question since long before the Final Notice was published.

Our Exosome Classification and Compliance Assessment is built around the framework set out above. Engagements typically include:

• Portfolio-wide classification review of every SKU containing exosomes, EVs, or CCM
• Source and supplier verification — including review of Certificates of Analysis and ingredient characterisation data
• Claims and advertising audit — across labels, websites, social media, influencer content, retailer pages, and clinic partner materials
• CNF / NPN / DIN pathway recommendation with documented rationale per SKU
• Reformulation or de-claim strategy for SKUs that can remain cosmetic
• NHP licensing support where the NPN pathway is viable
• Drug and biologic submission planning — including CTO Regulations compliance for human-derived materials
• GMP and quality system development for brands moving into drug- or biologic-pathway manufacturing
• Border and import compliance — to prevent section 30 detentions
• Inspection-readiness preparation in advance of Health Canada engagement

We also support skin-care and medi-aesthetic brands across related programs: Cosmetics and Personal Care market entry, Pharmaceuticals and biologic submissions, Natural Health Products licensing, and Regulatory Affairs and import/export strategy.

Learn more about MFLRC's full regulatory consulting services at mflrc.com

Frequently Asked Questions About Health Canada's Exosome Final Notice

Q: When did Health Canada publish the Final Notice on exosome topical product classification?

Health Canada's original consultation Notice was posted on 14 August 2025 (file 25-104893-244), followed by a 75-day consultation period that closed in October 2025. The Final Notice followed in April 2026 and addresses topical products containing human-derived exosomes, human extracellular vesicles, and/or human cell-conditioned media.

Q: Are all exosome skincare products now drugs in Canada?

No. Health Canada has taken a case-by-case classification approach. The product's source, processing, intended use, claims, route of administration, and target population are all weighed. However, most human-derived exosome topical products making structure/function or therapeutic claims will be classified as drugs, and frequently as biologics.

Q: Can I still sell an exosome serum as a cosmetic in Canada?

Possibly — but only if the source is not human-derived, the product is intended for healthy intact skin, the claims are limited to cleansing, beautifying, perfuming, or altering appearance, and there is no therapeutic or structure/function representation anywhere in the marketing chain. The Cosmetic Notification Form must be filed within ten days of first sale.

Q: Are "plant-derived" or "synthetic" exosome products exempt from the Final Notice?

No. While the Final Notice's title focuses on human-derived material, claims and intended use govern classification regardless of source. A plant-derived exosome product making regenerative or therapeutic claims is still a drug.

Q: What is the difference between an exosome drug and an exosome biologic in Canada?

A drug requires a Drug Identification Number (DIN) and a New Drug Submission. A biologic is a sub-category of drug (Schedule D of the Food and Drugs Act) that includes products derived from biological sources, with more rigorous donor, processing, viral safety, and lot-release requirements. Human-derived exosomes are biologics by default and additionally engage the Safety of Human Cells, Tissues and Organs for Transplantation Regulations.

Q: What about exosome products used during micro-needling or after laser procedures?

Application to broken or compromised skin is not a cosmetic route of administration. Products marketed or used in micro-needling, fractional laser, micro-channelling, or other skin-breaching protocols are almost always drugs, and where human-derived, biologics.

Q: What are the penalties for selling a non-compliant exosome product in Canada?

Enforcement tools include section 9 violations (false or misleading representation), section 30 importation prohibitions with border detention, mandatory recalls, public advisories, administrative monetary penalties, and prosecution under the Food and Drugs Act — including fines and, in severe cases, imprisonment.

Q: How long does it take to bring an exosome product into compliance?

For products that can remain cosmetic with reformulation and de-claiming, 30 to 90 days is typical. For products requiring NHP licensing, the timeline depends on Class I/II/III pathway selection and product file completeness. For drug or biologic submissions, the timeline extends to multiple years and requires non-clinical and clinical evidence. MFLRC's role is to help brands identify the fastest defensible path per SKU.

Take the Next Step: Book Your Exosome Classification and Compliance Assessment

The Final Notice has closed the regulatory grey zone for exosome, extracellular vesicle, and cell-conditioned media products in Canada. Brands that continue to operate inside that zone are exposed to label revision orders, CNF withdrawals, border detention, advertising prosecution, retailer delisting, and public advisory risk — all of which are materially more damaging than the cost of a structured regulatory review.

Contact MFLRC today to book your Exosome Classification and Compliance Assessment. Our senior consultants will review your portfolio, classify each SKU against the Final Notice and Health Canada's broader Drug or Cosmetic? framework, and deliver a documented, defensible pathway for every product — cosmetic, NHP, drug, or biologic — together with the label, advertising, and submission workstreams required to get there.

📧 info@mflrc.com • 📞 +1-647-492-5301 • 🌐 www.mflrc.com

Navigate Regulatory Complexity with Confidence.